Compared to Estimates, HCA (HCA) Q3 Earnings: A Look at Key Metrics

For the quarter ended September 2025, HCA Healthcare (HCA) reported revenue of $19.16 billion, up 9.6% over the same period last year. EPS came in at $6.96, compared to $5.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $18.5 billion, representing a surprise of +3.55%. The company delivered an EPS surprise of +23.19%, with the consensus EPS estimate being $5.65.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue per Equivalent Admission: $18,446.00 compared to the $17,966.71 average estimate based on five analysts.Equivalent Admissions: 1.04 billion versus 1.03 billion estimated by five analysts on average.Admissions: 577.8 million versus 575.37 million estimated by three analysts on average.Patient Days: 2,692.51 Days compared to the 2,718.89 Days average estimate based on two analysts.Average Length of Stay: 5 versus 5 estimated by two analysts on average.Number of hospitals: 191 versus 191 estimated by two analysts on average.Inpatient Revenue per Admission: $19,908.00 compared to the $19,196.22 average estimate based on two analysts.Equivalent Patient Days: 4.84 million versus the two-analyst average estimate of 4.86 million.Licensed Beds at End of Period: 50,577 versus the two-analyst average estimate of 50,346.Number of freestanding outpatient surgery centers: 123 compared to the 124 average estimate based on two analysts.View all Key Company Metrics for HCA here>>>Shares of HCA have returned +6.1% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HCA Healthcare, Inc. (HCA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks